<DOC>
	<DOCNO>NCT01178944</DOCNO>
	<brief_summary>This phase II trial study well pralatrexate oxaliplatin work treat patient esophageal , stomach , gastroesophageal junction cancer remove surgery spread primary site ( place start ) place body . Pralatrexate may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , oxaliplatin , work different way stop growth tumor cell , either kill cell , stop dividing , stop spread . Giving pralatrexate oxaliplatin may effective treatment esophageal , stomach , gastroesophageal junction cancer .</brief_summary>
	<brief_title>Pralatrexate Oxaliplatin Treating Patients With Unresectable Metastatic Esophageal , Stomach , Gastroesophageal Junction Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine overall response rate patient advance esophago-gastric cancer ( EGC ) combination pralatrexate oxaliplatin . SECONDARY OBJECTIVES : I . To examine toxicity tolerability regimen . II . To determine time-to-progression overall survival use regimen . III . To examine whether functionally relevant polymorphism gene folate metabolism pathway correlate efficacy toxicity pralatrexate . IV . To examine whether response pralatrexate predict micro-ribonucleic acid ( microRNA ) expression profile epithelial component tumor . OUTLINE : Patients receive pralatrexate intravenously ( IV ) 3-5 minute oxaliplatin IV 2 hour day 1 . Courses repeat every 2 week absence disease progression unacceptable toxicity . Oxaliplatin discontinue 12 course . After completion study treatment , patient follow 30 day periodically thereafter 5 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>10-deazaaminopterin</mesh_term>
	<mesh_term>Aminopterin</mesh_term>
	<criteria>Histologically confirm carcinoma esophagus , stomach gastroesophageal junction metastatic , locally advance inoperable cure ; histological subtypes permit include adenocarcinoma , squamouscell carcinoma , undifferentiated carcinoma ; smallcell carcinoma variant eligible No previous systemic therapy metastatic recurrent disease ; therapy ( chemotherapy , radiotherapy , ) administer neoadjuvant , adjuvant , definitive setting previously localize disease permit , provide complete 6 month prior enrollment ; palliative radiotherapy permit provide complete &gt; = 3 week prior study therapy initiation Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Life expectancy &gt; = 12 week Hemoglobin &gt; = 9 g/dl Absolute neutrophil count &gt; = 1500/mm^3 Platelet count &gt; = 100,000/mm^3 Serum creatinine = &lt; institutional upper limit normal ( ULN ) Bilirubin = &lt; 1.5 x ULN Transaminases = &lt; 3 x ULN ; document liver metastasis , transaminases 5 x ULN permit No evidence &gt; = grade 2 peripheral neuropathy Patients reproductive potential must willing use adequate contraceptive method ( e.g. , abstinence , intrauterine device , oral contraceptive , barrier device spermicide surgical sterilization ) treatment three month complete treatment ; negative pregnancy test require woman childbearing potential ; nurse woman ineligible Written , inform consent Hypersensitivity platinum compound Uncontrolled intercurrent illness include limited active infection , symptomatic congestive heart failure , unstable angina , uncontrolled cardiac arrhythmia , psychiatric illness would limit compliance study requirement Presence brain metastasis Patients thirdspace ( pleural , peritoneal ) fluid controllable usual drainage method eligible History second primary malignancy within 3 year prior enrollment , except insitu cervix carcinoma nonmelanoma skin cancer Undergone allogeneic stem cell transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>